Memphasys Launches AU$2 Million Capital Raise for Japanese Clinical Trial
Biotech business Memphasys (ASX:MEM) launched a AU$1 million capital raise and AU$1 million share purchase plan to fund a clinical trial in Japan, according to a Thursday filing with the Australian bourse.
The Japanese clinical trial, an equine fertility study named Felix, will advance strategic partnership talks and help sales in the Japanese market, the filing stated.
The placement and purchase plan are priced at the lower of AU$0.008 and a 20% discount to the company's five-day volume weighted average price, according to the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.